Bluejay Diagnostics (BJDX) AI Stock Analysis

• Market Cap: $1.99M
• Dividend Yield: N/A
• Average Volume (3M): 5.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: 97.70%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 972,000
• 10 Day Avg. Volume: 15,571,172
• 30 Day Avg. Volume: 5,266,425
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.11
• Enterprise Value/Market Cap: -1.01
• Enterprise Value/Revenue: -9.30
• Enterprise Value/Gross Profit: 145.31
• Enterprise Value/Ebitda: 0.30
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $3.50 ▲(438.46% Upside)
• Action: Reiterated Date: 01/23/26
• Date: Action: Reiterated 01/23/26

The score is held down primarily by weak financial performance (no meaningful revenue, sizable losses, and sustained negative free cash flow) despite low debt. Technicals add only modest support with a short-term bounce but a longer-term downtrend. Corporate events are positive for operational progress, but long regulatory/financing timelines and a negative P/E keep overall risk elevated.

Positive Factors

Commercial-scale antibody capacity

Completing commercial-scale IL-6 antibody production materially reduces a key manufacturing bottleneck for the Symphony cartridge. Sustained in-house antibody supply improves scalability and gross-margin potential once the platform is cleared, shortening ramp time and lowering supplier risk.

Low financial leverage

Very low reported debt reduces near-term solvency pressure and interest burden, giving management more optionality on financing routes. This structural balance-sheet strength lowers the probability of distress compared with highly leveraged peers while the firm progresses toward commercialization.

Focused point-of-care diagnostics strategy

A clear product focus on rapid, near-patient immunoassays for acute care/sepsis aligns with enduring clinical demand for faster diagnostics. A differentiated, clinician-facing use case supports durable adoption potential and reimbursement pathways once performance and regulatory requirements are met.

Negative Factors

Pre-commercial with no revenue

Zero trailing revenue and persistent multi-million-dollar operating losses imply the business is unproven commercially. This fundamental gap forces reliance on successful clinical validation and regulatory approval to unlock revenue, making current valuation dependent on future execution rather than present cash flows.

Sustained negative cash flow

Ongoing, material negative operating and free cash flow indicates the company cannot self-fund development and commercialization. Persistent cash burn increases the need for external capital, raising dilution risk and creating execution uncertainty over the next several quarters to years.

Regulatory timeline dependent on financing

A targeted 510(k) submission in 2027 that requires additional funding creates a structural timing and execution risk. Regulatory milestones are multi-year and contingent on capital; delays or funding shortfalls would prolong commercialization, extend cash burn, and increase strategic and dilutionary uncertainty.

Bluejay Diagnostics Business Overview & Revenue Model

Company Description

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Bluejay Diagnostics generates revenue through the sale of its Symphony System and associated consumables. The Symphony System is marketed to hospitals, clinics, and other healthcare facilities that require rapid diagnostic testing capabilities. The company may also engage in partnerships or collaborations with other healthcare entities to expand the reach and application of its technology. Additionally, Bluejay may generate revenue from licensing its technology or entering into strategic alliances with larger diagnostic or healthcare companies. These key revenue streams, along with potential government or institutional contracts, contribute to the company's overall earnings.

Bluejay Diagnostics Financial Statement Overview

Summary

Financial profile remains high-risk: the company is effectively pre-commercial with $0 TTM revenue, large and persistent losses (TTM operating loss ~-$7.0M; net loss ~-$6.9M), and continued cash burn (TTM operating/FCF ~-$6.3M). A partial offset is low leverage (debt ~ $0.14M vs equity ~ $3.69M), but equity has shrunk materially over time, keeping dilution/financing risk elevated.

Income Statement

The company remains pre-commercial, with revenue at $0 in TTM (Trailing-Twelve-Months) and most annual periods (except 2022 at ~$0.25M). Losses are large and persistent, with TTM operating loss of about $7.0M and net loss of about $6.9M, showing limited evidence of meaningful operating leverage so far. A modest positive is that the TTM net loss is smaller than 2024, but profitability is still far from breakeven and margins are deeply negative.

Balance Sheet

Leverage is low, with TTM debt of ~$0.14M against equity of ~$3.69M (low debt relative to equity), which reduces near-term solvency risk. However, the equity base has declined significantly versus prior years (from ~$11.5M in 2022 to ~$3.7M TTM), reflecting ongoing losses and cash burn. Returns on equity are materially negative, indicating continued value dilution unless the company can scale revenue.

Cash Flow

Cash generation is weak, with TTM operating cash flow around -$6.3M and free cash flow around -$6.3M, indicating continued funding needs. Free cash flow burn improved versus 2024 (less negative), but TTM free cash flow growth is sharply negative, highlighting volatility and an uneven trajectory. Cash burn broadly tracks reported losses, suggesting limited non-cash addbacks and no clear path yet to self-funding operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	216.09K	0.00	0.00	249.04K	0.00	0.00
Gross Profit	-13.83K	-199.10K	-780.96K	48.91K	-145.72K	-157.04K
EBITDA	-6.74M	-6.70M	-9.17M	-9.01M	-3.08M	-1.04M
Net Income	-6.85M	-7.72M	-9.95M	-9.30M	-3.73M	-1.13M
Balance Sheet
Total Assets	4.89M	6.66M	4.87M	13.52M	21.02M	1.52M
Cash, Cash Equivalents and Short-Term Investments	3.08M	4.30M	2.21M	10.11M	19.05M	912.36K
Total Debt	142.99K	222.25K	352.98K	492.62K	0.00	1.06M
Total Liabilities	1.20M	927.92K	1.97M	1.98M	637.16K	5.72M
Stockholders Equity	3.69M	5.73M	2.89M	11.54M	20.38M	-4.21M
Cash Flow
Free Cash Flow	-6.34M	-8.13M	-9.02M	-8.94M	-4.39M	-508.71K
Operating Cash Flow	-6.34M	-7.82M	-8.31M	-7.74M	-4.37M	-508.71K
Investing Cash Flow	-1.13K	-306.78K	-704.17K	-1.20M	-23.95K	0.00
Financing Cash Flow	3.67M	10.22M	1.11M	8.07K	22.53M	1.33M

Bluejay Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 2.70, below the 50-day MA of 2.85, and below the 200-day MA of 5.72, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 33.84 is Neutral, neither overbought nor oversold. The STOCH value of 23.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BJDX.

Bluejay Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BJDX	46 Neutral	$1.99M	-0.02	-126.20%	―	―	97.70%
TIVC	45 Neutral	$2.08M	-0.09	-178.18%	―	-49.63%	82.22%
AEMD	44 Neutral	$2.64M	-0.04	-191.39%	―	―	76.53%
VERO	41 Neutral	$576.33K	>-0.01	-854.61%	―	-12.39%	44.61%
DHAI	37 Underperform	$5.23K	>-0.01	―	―	―	―

Bluejay Diagnostics Corporate Events

Bluejay Diagnostics Completes 1-for-4 Reverse Stock Split

On June 18, 2025, stockholders of Bluejay Diagnostics approved an amendment to the company’s charter to permit a reverse stock split at ratios between 1-for-2 and 1-for-20, and on January 27, 2026 the board selected a 1-for-4 ratio, filing a certificate of amendment in Delaware to implement the move. The 1-for-4 reverse stock split took effect at 12:01 a.m. Eastern Time on January 29, 2026, after which Bluejay’s common stock began trading on Nasdaq on a post-split basis under the unchanged ticker “BJDX” but with a new CUSIP, consolidating every four outstanding shares into one and cutting the share count from about 2,834,133 to roughly 708,533, with prefunded warrant shares and all equity awards and warrants adjusted proportionately. The reverse split, which leaves par value and voting rights intact and treats all stockholders uniformly, is operationally significant because it sharply reduces the number of shares outstanding while preserving ownership percentages, and it streamlines the capital structure for investors and warrant holders, who will see automatic adjustments in book-entry and street-name accounts and receive cash in lieu of fractional shares.

The most recent analyst rating on (BJDX) stock is a Hold with a $0.87 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.

Bluejay Diagnostics Scales IL-6 Antibody Production Capacity

On December 29, 2025, Bluejay Diagnostics announced it had completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a key biomarker for inflammatory and critical-care applications, with both antibody types meeting internal performance criteria for use in Symphony cartridge manufacturing. Internal testing showed acceptable binding, specificity and signal performance for the monoclonal detection antibodies, and the company now estimates its IL-6 antibody inventory could support production of more than nine million Symphony cartridges while also having the capability to produce additional antibodies, marking a significant operational milestone for scaling the Symphony platform even as the system remains under development and subject to further validation and regulatory review.

Bluejay Diagnostics Reports Q3 Results and Updates

On November 10, 2025, Bluejay Diagnostics announced its third-quarter financial results and corporate updates, highlighting advancements in clinical milestones and strategic partnerships. The company reported progress in the SYMON-II clinical trial, aiming for FDA clearance and product commercialization, and completed a private placement transaction in October 2025. Bluejay is focused on sepsis diagnostics, with plans to submit a 510(k) application to the FDA in 2027, contingent on securing further financing.